10-Q: ARS Pharma Reports Strong neffy Sales Amid Global Launch

ARS Pharmaceuticals reports significant revenue growth from its needle-free epinephrine product, neffy, following its U.S. and EU commercial launches, despite increased operating losses due to aggressive market expansion.

Summary

• Total revenue for the six months ended June 30, 2025, surged to $23.7 million, up from $0.5 million in the same period of 2024, driven by the commercial launch of neffy.
• Net product revenue from neffy sales reached $20.6 million for the six months ended June 30, 2025, compared to zero in the prior year period.
• The company incurred a net loss of $78.8 million for the six months ended June 30, 2025, significantly higher than the $22.8 million loss in the prior year, primarily due to increased selling, general, and administrative expenses.
• Selling, general and administrative expenses increased by $78.5 million to $95.4 million for the six months ended June 30, 2025, reflecting substantial investments in marketing and sales force expansion.
• Research and development expenses decreased by $5.1 million to $7.0 million for the six months ended June 30, 2025.
• Cash, cash equivalents, and short-term investments totaled $240.1 million as of June 30, 2025.
• Net cash used in operating activities increased to $80.3 million for the six months ended June 30, 2025, from $14.0 million in the prior year period.
• neffy 2 mg received FDA approval on August 9, 2024, and commercial launch in the U.S. began on September 23, 2024.
• neffy 1 mg received FDA approval on March 5, 2025, with commercial launch in the U.S. starting on May 7, 2025.
• EURneffy (neffy 2 mg) received European Commission marketing authorization on August 22, 2024, and launched in Germany in June 2025 through a collaboration with ALK.
• Approval for EURneffy in the United Kingdom was granted in July 2025, with commercial launch anticipated in late second half of 2025.
• Regulatory reviews for neffy are ongoing in Canada, China, Japan, and Australia, with decisions expected by year-end 2025 for Japan, Canada, and Australia, and in the first half of 2026 for China.
• A Phase 2b clinical trial for chronic spontaneous urticaria patients was initiated in Q2 2025, with topline data expected in H1 2026.
• The U.S. addressable market opportunity for neffy is estimated at approximately $10 billion annually, targeting 20 million diagnosed patients with Type I allergic reactions.
• Remaining zero-cost inventory of $9.8 million as of June 30, 2025, is expected to be depleted by mid-2026.

Sentiment

Score: 7

Explanation: The company demonstrates strong progress with significant revenue growth from its newly launched, first-in-class product, neffy, and successful international expansion through strategic partnerships. While substantial net losses and increased cash burn are noted, these are expected as the company invests heavily in commercialization and market penetration. The large addressable market and ongoing development for additional indications present significant future potential, outweighing the typical risks associated with a growth-stage biopharmaceutical company.

Positives

• Achieved significant revenue growth, with net product sales of $20.6 million for the six months ended June 30, 2025, compared to zero in the prior year, demonstrating successful commercialization initiation.
• Secured FDA approval for both neffy 2 mg and 1 mg doses, expanding the addressable patient population in the U.S. to include children aged four and older weighing 15 kg to less than 30 kg.
• Obtained European Commission marketing authorization for EURneffy 2 mg and successfully launched in Germany through the ALK collaboration, marking initial international market penetration.
• Received UK approval for EURneffy 2 mg, with commercial launch expected in late H2 2025, further expanding international reach.
• Established a strategic ALK Collaboration Agreement, including a $145.0 million upfront payment and potential for up to $315.0 million in additional milestones and tiered royalties, providing substantial non-dilutive funding and market access.
• Initiated a co-promotion agreement with ALK U.S. to target up to 9,000 pediatricians and other prescribers in the U.S., enhancing sales force reach and market penetration.
• Reported positive topline results for neffy in treatment-refractory chronic urticaria patients and initiated a Phase 2b clinical trial, indicating potential for additional indications and market expansion.
• Maintained a strong cash position with $240.1 million in cash, cash equivalents, and short-term investments as of June 30, 2025, projected to fund operations for at least the next three years.

Negatives

• Incurred substantial net losses, with a net loss of $78.8 million for the six months ended June 30, 2025, an increase from $22.8 million in the prior year, reflecting high commercialization costs.
• Experienced a significant increase in selling, general and administrative expenses, rising by $78.5 million to $95.4 million for the six months ended June 30, 2025, due to marketing and sales force build-out.
• Net cash used in operating activities increased to $80.3 million for the six months ended June 30, 2025, indicating a high cash burn rate as commercialization scales up.
• Faces ongoing legal proceedings, including an opposition with the European Patent Office regarding a key patent and a trade secrets lawsuit filed by Aptar, which could incur substantial costs and divert resources.
• Highly dependent on the commercial success of neffy, with any failure to achieve market acceptance or adequate reimbursement severely hindering business and stock price.
• Relies completely on third parties for manufacturing and warehousing, introducing risks of supply interruptions, delays, and price fluctuations.
• Subject to potential product liability lawsuits inherent in pharmaceutical product commercialization and clinical testing.

Risks

• High dependence on the successful commercialization of neffy in the United States and EU; commercial failure would materially adversely affect business and stock price.
• neffy and future intranasal epinephrine technology product candidates may fail to achieve sufficient market acceptance by physicians, patients, caregivers, and third-party payors.
• Inability to achieve and maintain adequate levels of third-party payor coverage and reimbursement for neffy on reasonable pricing terms could severely hinder commercial success.
• Competitive products may reduce or eliminate the commercial opportunity for neffy, especially if competitors develop more rapidly or offer more effective/safer alternatives.
• Failure or significant delays in developing neffy for additional indications (e.g., urticaria) or other intranasal epinephrine technology product candidates would limit commercial potential.
• FDA may not conclude that future product candidates or additional indications satisfy Section 505(b)(2) regulatory approval pathway requirements, leading to longer, costlier, and riskier approval processes.
• Product liability lawsuits against the company or its partners could divert resources, incur substantial liabilities, and limit commercialization.
• Compromised information technology systems or data, or those of third parties, could lead to regulatory investigations, litigation, fines, business disruptions, and reputational harm.
• Complete reliance on third parties to manufacture and warehouse domestic and international supply of neffy and product candidates introduces supply chain risks.
• Dependence on international third-party licensees for development and commercialization outside the U.S.; their failure to perform could adversely affect business.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect business, financial condition, and results of operations.
• Timing of sales and results of operations are expected to fluctuate, making future performance difficult to predict.
• Significant accumulated losses since inception, with expectations of continued losses for the foreseeable future.
• Need for additional funding; inability to raise capital when needed could force delays, reductions, or elimination of product development or commercialization efforts.
• Inability to obtain and maintain sufficient intellectual property protection for neffy and other proprietary technologies could harm competitive position.
• Increasing use of social media platforms presents new risks and challenges related to compliance and public perception.
• Recently enacted and future legislation (e.g., IRA, OBBBA) may increase the difficulty and cost to commercialize products and affect pricing.
• Disruptions at the FDA, including workforce reductions or inadequate funding, could prevent timely review and approval of submissions.
• Foreign governments may impose strict price controls, adversely affecting revenues.
• Business activities may be subject to FCPA and similar anti-bribery/anti-corruption laws, as well as export controls and trade sanctions.
• Relationships with customers, healthcare professionals, and third-party payors are subject to healthcare laws, potentially leading to penalties for non-compliance.
• Inability to protect the confidentiality of trade secrets would harm business and competitive position.
• Claims that employees, consultants, or contractors wrongfully used or disclosed confidential information of third parties could lead to litigation and adverse impacts.
• Future need to obtain additional licenses of third-party technology, which may not be available or only on commercially unreasonable terms.
• Difficulties in managing growth, including expanding headcount and infrastructure, could disrupt operations.
• The market price of common stock could be volatile due to various factors, including financial performance, regulatory decisions, and competitive landscape.
• Delaware law and corporate provisions could make a merger, tender offer, or proxy contest difficult, potentially depressing stock price.
• Exclusive forum provisions in the certificate of incorporation could limit stockholders' ability to choose a favorable judicial forum.
• Future sales of shares by existing stockholders could cause the stock price to decline.
• Geo-political conditions, such as the Russia-Ukraine conflict and Middle East conflict, may have serious adverse consequences on business and financial condition.

Future Outlook

The company anticipates operating expenses to increase for the foreseeable future, driven by commercialization activities for neffy, ongoing clinical development for additional indications, and maintaining public company compliance. Existing cash, cash equivalents, short-term investments, and revenues from product sales and collaboration agreements are expected to be sufficient to meet anticipated cash requirements for at least the next three years. Future funding requirements will depend on the scope and costs of development, manufacturing, marketing, and regulatory approvals. The company plans to continue evaluating its intranasal epinephrine technology for other potential indications, such as urticaria, with topline data from a Phase 2b trial anticipated in the first half of 2026, potentially followed by a pivotal efficacy study in 2026. Regulatory decisions for neffy in Japan, Canada, and Australia are expected by year-end 2025, with commercial rollouts planned for the first half of 2026, and a decision for China in the first half of 2026.

Management Comments

• We believe neffy's no needle, no injection approach addresses a significant unmet need in the use of epinephrine, which, except for neffy, is currently approved only in injectable formulations for the emergency treatment of Type I allergic reactions.
• We believe neffy's and our intranasal epinephrine technology product candidates design, particularly the compact size and no needle, no injection delivery, eliminates needle-related apprehension and pain, improves portability and ease of use, is highly reliable, and will increase prescriptions for epinephrine, making it more likely that patients and caregivers will administer epinephrine sooner, achieve more rapid symptom relief, and prevent the allergic reaction from progressing to a level of severity that could lead to hospitalization or even death.
• Our launch strategy for neffy in the United States involves direct outreach to high-volume prescribers of epinephrine accounting for approximately 55% of prescriptions in the last year through an efficient sales force.
• Based on our current operating plan, we believe that our existing cash, cash equivalents, short-term investments, and revenues from product sales and cash proceeds from collaboration and out-licensing agreements will be sufficient to meet our anticipated cash requirements through at least the next three years.

Industry Context

ARS Pharmaceuticals operates in the highly competitive biopharmaceutical industry, specifically targeting the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is positioned as a disruptive innovation, being the first and only FDA and European Commission-approved needle-free epinephrine product and the first new delivery method in over 35 years. This addresses a significant unmet need related to needle apprehension, pain, and portability issues associated with traditional epinephrine autoinjectors. The company competes with established injectable products like EpiPen (Viatris, Teva), Adrenaclick (Amneal), Auvi-Q (Kaleo), and Symjepi (Sandoz), as well as other developing intranasal and sublingual candidates from companies such as Bryn Pharma, Nasus Pharma, Hikma, Orexo AB, and Aquestive Therapeutics. The company's strategy focuses on capturing a significant portion of the estimated $10 billion U.S. annual market opportunity by leveraging neffy's unique delivery method and expanding into international markets through strategic partnerships.

Comparison to Industry Standards

• neffy is the first and only FDA and European Commission-approved needle-free epinephrine product, representing a significant advancement over traditional injectable formulations like EpiPen (Viatris, Teva Pharmaceuticals), Adrenaclick (Amneal Pharmaceuticals), Auvi-Q (Kaleo, Inc.), and Symjepi (Sandoz, Inc.).
• Studies of neffy demonstrated nasally delivered epinephrine reached blood levels comparable to those of already approved epinephrine injectable products, indicating similar efficacy profiles to established market leaders.
• neffy showed statistically significant responses compared to injection on pharmacodynamic surrogates for efficacy even one minute after dosing, suggesting a rapid onset of action comparable to or potentially faster than some existing solutions.
• The company's estimated U.S. addressable market opportunity of approximately $10 billion (combining $3 billion from currently prescribed patients and $7 billion from undiagnosed/untreated patients) is substantial, indicating a large potential for market capture compared to the current sales of existing epinephrine autoinjectors.
• The company's strategy to address the 90% of patients not achieving optimal treatment outcomes with current devices due to needle-related drawbacks positions neffy as a potentially superior alternative to the current standard of care.

Corporate Governance

Legal Proceedings

• Aera A/S filed a notice of opposition with the European Patent Office (EPO) on July 24, 2023, regarding EP 3678649, a patent for a nasal spray formulation of epinephrine. Oral proceedings are scheduled for October 7, 2025.
• Aptargroup, Inc. and Aptar France SAS filed a lawsuit against the company on March 25, 2025, in the U.S. District Court for the Southern District of New York, alleging violations of the Defend Trade Secrets Act, misappropriation of trade secrets under New York state law, and various breaches of contract. The company filed a motion to dismiss on June 12, 2025, and Aptar filed opposition on July 28, 2025.

Related Party Transactions

• Consulting agreement with Pacific-Link Regulatory Consulting, Inc. (owned by President/CEO/director and Chief Medical Officer) for regulatory and development services: $0.6 million for Q2 2025, $1.3 million for H1 2025.
• Consulting agreement with Marlinspike Group, LLC (managing member is Chair of Board of Directors) for management, business consulting, and business development support: $0.1 million for Q2 2025 and H1 2025.
• Consulting agreement with a Board of Directors member for general advice and assistance: less than $0.1 million in stock-based compensation expense for Q2 2025 and H1 2025.
• Royalty payments to OrbiMed Advisors LLC (a General Partner at OrbiMed is a Board of Directors member) for rights purchased from Aegis: $0.9 million for Q2 2025, $1.4 million for H1 2025.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through successful commercialization of neffy and pipeline expansion, but also exposed to significant operating losses and potential future dilution from capital raises.
• Employees: Increased headcount (from 23 to 162 full-time employees) and expansion of sales, marketing, and administrative functions indicate growth opportunities, but also challenges in managing rapid expansion and retaining key talent.
• Customers (patients and caregivers): Benefit from a needle-free epinephrine option addressing unmet needs, potentially leading to earlier administration and improved outcomes for Type I allergic reactions.
• Healthcare Professionals (HCPs): Targeted by expanded sales and co-promotion efforts (e.g., ALK U.S. targeting pediatricians), indicating increased awareness and access to neffy.
• Third-party Payors: Commercial success depends on favorable coverage and reimbursement, which may involve ongoing negotiations and potential pricing pressures.
• Suppliers/Manufacturers: Continued reliance on third-party manufacturers (Renaissance, Ompi) and raw material suppliers, indicating ongoing business for these partners but also concentration risk for the company.

Next Steps

• Continue commercialization efforts for neffy 2 mg and 1 mg in the United States.
• Continue commercialization efforts for EURneffy in the EU and prepare for UK launch in late H2 2025.
• Await regulatory decisions for neffy in Japan, Canada, and Australia by year-end 2025, and China in H1 2026.
• Initiate commercial rollouts in Japan, Canada, and Australia in H1 2026.
• Continue the Phase 2b randomized, placebo-controlled outpatient clinical trial for chronic spontaneous urticaria patients, with topline data anticipated in H1 2026.
• Potentially initiate a single pivotal efficacy study for chronic spontaneous urticaria in 2026.
• Deplete remaining zero-cost inventory by mid-2026.
• Evaluate the provisions and potential effects of the One Big Beautiful Bill Act (OBBBA) on financial position, results of operations, and cash flows.
• Monitor and respond to legal proceedings, including the EPO opposition and Aptar lawsuit.

Key Dates

Recommendation

The company is in a critical growth phase, successfully launching a first-in-class, needle-free epinephrine product (neffy) in major markets (U.S., EU, UK) and expanding its global footprint through strategic partnerships. While current financial results show significant net losses and increased cash burn, these are expected investments for a commercial-stage biopharmaceutical company aiming to capture a large, underserved market. The strong cash position, coupled with the potential for substantial milestone payments and royalties from collaborations, provides a solid financial runway. The ongoing development for additional indications, such as urticaria, further enhances long-term growth prospects. For a seasoned investor with a long-term horizon and tolerance for growth-stage volatility, the disruptive potential of neffy and the company's execution on its commercial strategy make it an attractive investment.

Keywords

neffy, epinephrine, anaphylaxis, allergic reactions, intranasal drug delivery, biopharmaceutical, FDA approval, European Commission approval, commercialization, drug launch, Type I allergic reactions, ALK collaboration, pharmaceutical sales, biotech, drug development, urticaria